Business Description
Inozyme Pharma Inc
NAICS : 541714
SIC : 2834
ISIN : US45790W1080
Share Class Description:
INZY: Ordinary SharesDescription
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.05 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 36.9 | |||||
| 3-Year EPS without NRI Growth Rate | 35.5 | |||||
| 3-Year FCF Growth Rate | 25.5 | |||||
| 3-Year Book Growth Rate | -30.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 13.34 | |||||
| 9-Day RSI | 23.37 | |||||
| 14-Day RSI | 30.94 | |||||
| 6-1 Month Momentum % | 101.39 | |||||
| 12-1 Month Momentum % | -5.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.36 | |||||
| Quick Ratio | 13.36 | |||||
| Cash Ratio | 12.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.2 | |||||
| Shareholder Yield % | -10.91 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -56.66 | |||||
| ROA % | -42.44 | |||||
| ROIC % | -1034.9 | |||||
| ROC (Joel Greenblatt) % | -2157.22 | |||||
| ROCE % | -43.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.93 | |||||
| Price-to-Tangible-Book | 1.93 | |||||
| EV-to-EBIT | -2.01 | |||||
| EV-to-EBITDA | -2.04 | |||||
| EV-to-FCF | -1.92 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Price-to-Net-Cash | 2.11 | |||||
| Earnings Yield (Greenblatt) % | -49.75 | |||||
| FCF Yield % | -26.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INZY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inozyme Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.39 | ||
| Beta | 1.14 | ||
| Volatility % | 62.68 | ||
| 14-Day RSI | 30.94 | ||
| 14-Day ATR ($) | 0.450982 | ||
| 20-Day SMA ($) | 5.8505 | ||
| 12-1 Month Momentum % | -5.84 | ||
| 52-Week Range ($) | 2.689 - 7.795 | ||
| Shares Outstanding (Mil) | 61.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inozyme Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inozyme Pharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inozyme Pharma Inc Frequently Asked Questions
What is Inozyme Pharma Inc(INZY)'s stock price today?
The current price of INZY is $4.39. The 52 week high of INZY is $7.80 and 52 week low is $2.69.
When is next earnings date of Inozyme Pharma Inc(INZY)?
The next earnings date of Inozyme Pharma Inc(INZY) is .
Does Inozyme Pharma Inc(INZY) pay dividends? If so, how much?
Inozyme Pharma Inc(INZY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers